Cognition Therapeutics (CGTX) Projected to Post Quarterly Earnings on Thursday

Cognition Therapeutics (NASDAQ:CGTX) is expected to be issuing its Q2 2026 results before the market opens on Thursday, August 6th. Analysts expect the company to announce earnings of ($0.06) per share and revenue of $5.00 million for the quarter. Parties can check the company’s upcoming Q2 2026 earning results page for the latest details on the call scheduled for Friday, August 7, 2026 at 4:00 PM ET.

Cognition Therapeutics (NASDAQ:CGTX) last posted its quarterly earnings data on Thursday, May 7th. The company reported ($0.05) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.06) by $0.01. On average, analysts expect Cognition Therapeutics to post $-0 EPS for the current fiscal year and $-0 EPS for the next fiscal year.

Cognition Therapeutics Price Performance

Shares of NASDAQ CGTX opened at $0.90 on Thursday. Cognition Therapeutics has a 1 year low of $0.55 and a 1 year high of $3.83. The firm has a 50-day simple moving average of $1.16 and a two-hundred day simple moving average of $1.14. The company has a market cap of $80.65 million, a P/E ratio of -3.75 and a beta of 1.75.

Institutional Trading of Cognition Therapeutics

A number of hedge funds have recently bought and sold shares of CGTX. Gamco Investors INC. ET AL bought a new stake in Cognition Therapeutics during the 3rd quarter valued at $27,000. Private Management Group Inc. bought a new position in shares of Cognition Therapeutics in the 3rd quarter worth $32,000. Marshall Wace LLP bought a new position in shares of Cognition Therapeutics in the 4th quarter worth $37,000. Raymond James Financial Inc. lifted its stake in shares of Cognition Therapeutics by 34.7% during the 3rd quarter. Raymond James Financial Inc. now owns 29,641 shares of the company’s stock worth $40,000 after purchasing an additional 7,641 shares during the last quarter. Finally, XTX Topco Ltd purchased a new stake in shares of Cognition Therapeutics during the 4th quarter worth $50,000. Hedge funds and other institutional investors own 43.35% of the company’s stock.

Analyst Upgrades and Downgrades

Several brokerages have recently weighed in on CGTX. Weiss Ratings reiterated a “sell (d-)” rating on shares of Cognition Therapeutics in a report on Wednesday, June 24th. HC Wainwright restated a “buy” rating and set a $3.00 price objective on shares of Cognition Therapeutics in a report on Monday, June 22nd. Three investment analysts have rated the stock with a Buy rating and one has given a Sell rating to the stock. Based on data from MarketBeat, Cognition Therapeutics has an average rating of “Moderate Buy” and a consensus price target of $3.33.

Cognition Therapeutics Company Profile

Cognition Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on developing disease-modifying therapies for neurodegenerative disorders, with an emphasis on Alzheimer’s disease. The company’s lead investigational candidate, CT1812, is an oral small molecule that antagonizes the sigma-2 receptor complex to protect synapses from amyloid-beta oligomer toxicity. By targeting a novel mechanism of action, Cognition Therapeutics aims to slow or reverse cognitive decline in patients living with Alzheimer’s disease.

CT1812 has successfully completed Phase 1 safety studies and preliminary Phase 2a trials, and is currently being evaluated in multiple Phase 2 clinical studies across North America and Europe in patients with mild-to-moderate Alzheimer’s disease.